Diabetes mellitus Posts on Medivizor
Navigation Menu

Diabetes mellitus Posts on Medivizor

Canagliflozin versus sitagliptin in type 2 diabetes

Posted by on Mar 17, 2019 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study was to compare blood sugar control and weight loss in patients with type 2 diabetes (T2D) who were treated with canagliflozin compared to sitagliptin. The main finding was that patients treated with canagliflozin had better blood sugar control and greater weight loss than those treated with sitagliptin. Some...

Read More

Does empagliflozin help lower blood pressure in patients with diabetes and high night time blood pressure?

Posted by on Mar 17, 2019 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study was to monitor blood pressure changes with empagliflozin (Jardiance) treatment and normal blood pressure treatment in patients with type 2 diabetes (T2D) and uncontrolled night time high blood pressure. The main finding of the study was that these patients had reductions in their blood pressure when empagliflozin was...

Read More

Is it better to reduce basal insulin rate or remove insulin pump before exercise in type 1 diabetes?

Posted by on Mar 12, 2019 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study was to investigate if reducing basal insulin rate (BRR) 90-minutes before exercise was better at preventing hypoglycemia (dangerously low blood glucose) than suspending the insulin pump (pump suspension; PS) in type 1 diabetes (T1D). The main finding was that BRR 90-minutes before exercise improved blood glucose...

Read More

Resveratrol and diabetic kidney disease

Posted by on Mar 7, 2019 in Diabetes mellitus | 0 comments

In a nutshell This study aimed to investigate the effects of resveratrol on diabetic kidney disease. The main finding of the study was that resveratrol reduced the amount of protein lost in the urine in diabetic kidney disease. Some background Diabetic kidney disease (nephropathy) is a common complication of diabetes. One of the ways to measure kidney...

Read More

Does canagliflozin increase the risk of bone fractures in patients with type 2 diabetes?

Posted by on Mar 7, 2019 in Diabetes mellitus | 0 comments

In a nutshell This study aimed to investigate the effect of canagliflozin (Invokana) use on bone fracture risk in patients with type 2 diabetes (T2D). The main finding of the study was that there was no increased risk of bone fractures with canagliflozin use. Some background Canagliflozin is an SGLT-2 inhibitor, used to treat T2D. It works by...

Read More

The relationship between insulin dose and risk of heart disease in type 1 diabetes

Posted by on Feb 28, 2019 in Diabetes mellitus | 0 comments

In a nutshell The aim of the study was to look at the relationship between insulin dose and risk of cardiovascular disease (CVD) in type 1 diabetes (T1D). The main finding of the study was that higher insulin doses are associated with CVD risk factors but not with increased CVD events. Some background Patients with T1D have an increased risk of CVD...

Read More

Effect of long-acting exenatide on blood sugar, body weight and blood vessels in type 2 diabetes

Posted by on Feb 28, 2019 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study was to examine the effect of long-acting exenatide on blood sugar control, body weight and the thickness of the wall of the carotid artery in patients with type 2 diabetes (T2D). The main finding of the study was that this treatment improved all these parameters in patients with T2D. Some background Patients withT2D...

Read More

How safe and effective is ipragliflozin in the treatment of type 2 diabetes?

Posted by on Feb 28, 2019 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study was to investigate the safety and effectiveness of ipragliflozin (Suglat) in the treatment of type 2 diabetes (T2D). The main finding of the study was that ipragliflozin was safe effective in the treatment of T2D and improved liver function. Some background Ipragliflozin is a blood sugar lowering drug used...

Read More

The safety and effectiveness of a closed-loop insulin delivery system at day and night time

Posted by on Feb 27, 2019 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study was to investigate the safety and effectiveness of a closed-loop insulin delivery system for day and night use in patients with type 1 diabetes (T1D). The main finding of the study was that this system was safe and had better blood glucose control than the sensor-augmented pump. Some background Insulin therapy is...

Read More

Incretin-based antidiabetic drugs and heart failure

Posted by on Feb 24, 2019 in Diabetes mellitus | 0 comments

In a nutshell The aim of this study was to investigate the relationship between the use of incretin-based anti-diabetic drugs and the risk of hospitalization due to heart failure. The main finding of the study was that the use of these drugs is not associated with an increased risk of hospitalization due to heart failure. Some background There...

Read More